Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Q1: $3.9B Cash, Brepocitinib Launch on Track, $208.7M Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$35.1
Mkt Cap
$24.995B
52W Low
$10.9
52W High
$37
52W Position info
222% above low
Off High info
5.1% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $10.9.

Summary

Roivant reported Q1 results with $3.9 billion in cash (pre-Moderna payment), a $208.7 million buyback, and confirmation that brepocitinib's dermatomyositis launch is on track for September 2026.


Key Events · Earnings and Guidance · ROIV

  • Cash Fortress at $3.9B+

    Consolidated cash, equivalents, and marketable securities were $3.9 billion as of June 30, 2026, excluding the $950 million Moderna payment received in July, bringing total liquidity above $4.7 billion and extending cash runway into profitability.

  • $208.7M Share Repurchase

    Roivant repurchased 7.3 million common shares for approximately $208.7 million during the quarter, reducing share count and signaling management's confidence in the company's valuation.

  • Brepocitinib Launch Imminent

    Commercial preparations for brepocitinib in dermatomyositis are on track for launch by the end of September 2026, marking Roivant's transition to a commercial-stage biotech.

  • Catalyst-Rich Second Half 2026

    Topline data expected in H2 2026 from Phase 3 studies of brepocitinib in non-infectious uveitis, mosliciguat in PH-ILD, and IMVT-1402 proof-of-concept in cutaneous lupus erythematosus.


Analysis · ROIV · Life Sciences

A net loss of $290.6 million for the June quarter takes a back seat to the strength of the balance sheet and pipeline execution. Cash stands at $3.9 billion, and that's before the $950 million Moderna settlement payment received in July — total liquidity exceeds $4.7 billion, funding operations into profitability. Confidence in the valuation is underscored by the repurchase of 7.3 million shares for $208.7 million. Meanwhile, the dermatomyositis launch of brepocitinib remains on track for the end of September, with multiple Phase 3 readouts expected in the second half of 2026. A fortified cash position, an imminent commercial launch, and a catalyst-rich second half combine to make this a high-importance update.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $35.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $10.90 to $37.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info